Subscribe
Share
Share
Embed
Neuroscience Daily for 14 September covers 3 neuroscience stories on cognitive decline program, pouring control, alzheimer’s trial extensions. It is a compact audio briefing on studies, mechanisms, and the discussion around them.
Neuroscience Daily for 14 September follows 3 stories from r/neuro and r/neuroscience, moving through cognitive decline program, pouring control, alzheimer’s trial extensions.
The first story is about a personalized program for cognitive decline, described in a 2014 paper available through PubMed Central. The MEND program combined dietary, metabolic, sleep, exercise, and other individualized changes instead of testing one treatment in isolation.
The second story is about why humans can pour a cup of coffee so reliably, based on a bioRxiv preprint by Midlagajni and colleagues. The researchers measured continuous pouring across different containers, vessels, and speed demands, then modeled the task with a stochastic control framework that included flow dynamics, energy use, and each person’s preferred idea of Despite large differences in movement paths and durations, people tended to aim for an individually stable fill level.
The third story examines whether open-label extensions make Alzheimer’s antibody trials look more effective than their controlled phases, in a 2026 paper in BMJ Neurology Open. The authors simulated and compared cognitive-decline trajectories from the lecanemab Clarity-AD and donanemab TRAILBLAZER-ALZ 2 trials, paying particular attention to selective retention and the switch from double-blind treatment to open-label follow-up.
Episode closing.
The most talked-about neuroscience discoveries, studies and breakthroughs, distilled into a five-minute daily briefing. From brain health and cognition to sleep, memory and consciousness, stay on top of the research shaping how we understand the mind.